LTX-315 peptide shows activity against MRSA and other MDR clinical isolates

The wire

1. 01In vitro testing against six ATCC reference strains and six clinical isolates found LTX-315 MICs of 8-32 µM against reference strains and down to 4 µM against several MDR isolates, where chloramphenicol and kanamycin failed.
2. 02LTX-315 was developed as an oncolytic peptide; the data position it as a possible standalone antimicrobial or antibiotic adjuvant, with fourfold to 16-fold reductions in partner antibiotic dose.
3. 03Findings are laboratory-only, with no animal or human data on toxicity or systemic exposure reported in this Journal of Peptide Science paper.

From the source

Investigating LTX-315 as a Therapeutic Peptide: Antimicrobial Activity on Clinical Bacterial Isolates

Journal of peptide science : an official publication of the European Peptide Society · 2026 Nov · Khanh HT, Ngoc-Ngan TH, Phuong HBT et al.